FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies

Abstract Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. Methods Patients (≥20 years old) self‐administered oral pem...

Full description

Bibliographic Details
Main Authors: Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
advanced solid tumors
FGFR
Japanese patients
pemigatinib
phase 1 clinical trial
Online Access:https://doi.org/10.1002/cam4.5798

Internet

https://doi.org/10.1002/cam4.5798

Similar Items